CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company’s lead drug candidate TPI 287 and Berubicin, which completed Phase I clinical trial that is used for the treatment of glioblastoma and other CNS malignancies. CNS Pharmaceuticals, Inc. has license agreements with Houston Pharmaceuticals, Inc., Cortice Biosciences, Inc., and The University of Texas M.D. Anderson Cancer Center, as well as a collaboration and asset purchase agreement with Reata Pharmaceuticals, Inc. The company was incorporated in 2017 and is based in Houston, Texas.